Phase II
With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look.
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Vaccitech Ltd announced that its strategic collaboration with the Ludwig Institute for Cancer Research, Vaccitech Oncology Limited, has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer.
Shares of Minerva Neurosciences are down more than 22% in premarket trading after the company announced late Wednesday that its Phase IIb major depressive disorder (MDD) trial failed to meet primary and key secondary endpoints.
The FDA granted Astellas Pharma and Seattle Genetics accelerated approval for Padcev, a first-of-its-kind treatment for adult patients with metastatic urothelial bladder cancer.
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
The company indicated it is shutting down its gosuranemab program for PSP and other primary tauopathies.
AstraZeneca and Daiichi Sankyo presented positive data from their Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201) in HER2-positive metastatic breast cancer patients who received two or more previous HER-2 targeted regimens.
Companies from across the globe provide updates to their business and pipelines.
Data on 52 patients in the 145-patient clinical trial highlight ADCT-402 (loncastuximab tesirine) continues to demonstrate anti-tumor activity and manageable toxicity in heavily pretreated patients
PRESS RELEASES